Author: Ali, Ziad A.; El-Mallakh, Rif S.
Title: Nebulized Lidocaine in COVID-19, An Hypothesis Cord-id: gkb6c24f Document date: 2020_6_1
ID: gkb6c24f
Snippet: Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti
Document: Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adenosine triphosphatase: 1
- acute ards respiratory distress syndrome and adjunctive treatment: 1, 2, 3, 4
- acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and low airway: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung accumulation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung edema: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute pulmonary edema and adenosine triphosphatase: 1
- acute pulmonary edema and local anesthetic: 1
- acute pulmonary edema and lung accumulation: 1, 2, 3
- acute pulmonary edema and lung damage: 1, 2, 3
- acute pulmonary edema and lung edema: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute pulmonary edema cause and lung edema: 1, 2
- additional research and lung damage: 1, 2
- adenosine triphosphatase and lung edema: 1
- adjunctive treatment and lung accumulation: 1
- adjunctive treatment and lung damage: 1, 2, 3, 4
- administration route and lung accumulation: 1
- administration route and lung damage: 1
Co phrase search for related documents, hyperlinks ordered by date